Who is sponsoring NCT04871945?

NCT04871945 is sponsored by Hanyang University Seoul Hospital.

What condition does NCT04871945 study?

NCT04871945 studies Covid19, Vaccine Reaction, Hemolysis, End-stage Renal Disease.

Is NCT04871945 still recruiting?

NCT04871945 is currently completed. Last updated 17 March 2022.

Last reviewed 2022-03-17 · How we verify

NCT04871945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

Completed Last updated 17 March 2022

What this trial tests

trial testing Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA) in Covid19 in 31 participants. Completed in 31 October 2021.

Timeline

20 April 2021

Primary endpoint
30 September 2021

31 October 2021

Quick facts

Lead sponsor	Hanyang University Seoul Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	31
Start date	20 April 2021
Primary completion	30 September 2021
Estimated completion	31 October 2021
Sites	1 location across South Korea

Drugs / interventions tested

Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)

Conditions studied

Covid19 — all drugs for Covid19 →
Vaccine Reaction — all drugs for Vaccine Reaction →
Hemolysis — all drugs for Hemolysis →
End-stage Renal Disease — all drugs for End-stage Renal Disease →

Sponsor

Hanyang University Seoul Hospital

Who can join

18 and older, any sex, with Covid19 or Vaccine Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy.
Park JS, Minn D, Hong S, Jeong S, et al · · 2022 · cited 8× · PMID 35698835 · DOI 10.3346/jkms.2022.37.e180
SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?
Toapanta N, Bestard O, Soler MJ. · · 2021 · cited 5× · PMID 34289072 · DOI 10.1093/ndt/gfab227

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hanyang University Seoul Hospital trials

Trials by the same sponsor.

NCT06144021 — Efficacy and Safety of Kefir Whey Postbiotics · NA · recruiting
NCT06429644 — Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations · completed
NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
NCT04567134 — Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea · unknown
NCT04835883 — Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04871945 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hanyang University Seoul Hospital
Last refreshed: 17 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04871945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing